Efficacy and safety of the first-in-class imidazoline-2 receptor ligand CR4056 in pain from knee osteoarthritis and disease phenotypes: a randomized, double-blind, placebo-controlled phase 2 trial.
Osteoarthritis and Cartilage（2020）
Abstract
EudraCT 2015-001136-37.
MoreTranslated text
Key words
CR4056,Knee osteoarthritis,Imidazoline-2 receptor,Randomized controlled trial,Phenotypes
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined